Sec Form 3 Filing - Radosavljevic Danka @ Eton Pharmaceuticals, Inc. - 2026-07-31

FORM 3 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Radosavljevic Danka 2. Issuer Name and Ticker or Trading Symbol Eton Pharmaceuticals, Inc. [ ETON] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner X __ Officer (give title below) _____ Other (specify below) Chief Operating Officer (Last) (First) (Middle) C/ ETON PHARMACEUTICALS, INC., 21925 W. FIELD PARKWAY, SUITE 235 3. Date of Earliest Transaction (MM/DD/YY) 07/31/2026 (Street) DEERPARK, IL60010 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 22,473 D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Employee Stock Option (Right to Buy) $ 15.47 ( 1 ) 01/11/2036 Common Stock 31,508 D Restricted Stock Units $ 0 ( 3 ) ( 2 ) ( 2 ) Common Stock 20,039 D Restricted Stock Units $ 0 ( 3 ) ( 4 ) ( 4 ) Common Stock 7,194 D Employee Stock Option (Right to Buy) $ 13 ( 5 ) 01/02/2035 Common Stock 14,317 D Employee Stock Option (Right to Buy) $ 14.68 ( 6 ) 03/17/2035 Common Stock 10,000 D Employee Stock Option (Right to Buy) $ 4.42 ( 7 ) 02/12/2034 Common Stock 92,993 D Employee Stock Option (Right to Buy) $ 4.74 ( 8 ) 08/14/2033 Common Stock 10,000 D Employee Stock Option (Right to Buy) $ 3.47 ( 9 ) 02/19/2033 Common Stock 42,224 D Employee Stock Option (Right to Buy) $ 8.61 ( 10 ) 05/02/2031 Common Stock 35,000 D Employee Stock Option (Right to Buy) $ 3.58 ( 11 ) 03/11/2030 Common Stock 60,000 D Employee Stock Option (Right to Buy) $ 1.38 ( 12 ) 07/23/2027 Common Stock 18,742 D Common Stock $ 0 ( 13 ) ( 13 ) Common Stock 128,985 D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Radosavljevic Danka C/ ETON PHARMACEUTICALS, INC. 21925 W. FIELD PARKWAY, SUITE 235 DEERPARK, IL60010 Chief Operating Officer Signatures /s/ Judith Matthews 08/12/2026 Signature of Reporting Person Date

Explanation of Responses:

( 1 )The shares subject to the option shall vest in 48 equal monthly installments from the date of grant until fully vested and exercisable on January 12, 2030. ( 2 ) The restricted stock units vest in four equal annual installments beginning January 12, 2027, contingent upon the reporting person being employed by the issuer on the date(s) of vesting. ( 3 )Each restricted stock unit represents a contingent right to receive one share of ETON Common Stock. ( 4 )The restricted stock units vest in four equal annual installments beginning January 3, 2026, contingent upon the reporting person being employed by the issuer on the date(s) of vesting. ( 5 )The shares subject to the option shall vest in 48 equal monthly installments from the date of grant until fully vested and exercisable on January 3, 2029. ( 6 )The shares subject to the option shall vest in 48 equal monthly installments from the date of grant until fully vested and exercisable on March 18, 2029. ( 7 )The shares subject to the option shall vest in 48 equal monthly installments from the date of grant until fully vested and exercisable on February 13, 2028. ( 8 )The shares subject to the option shall vest in 48 equal monthly installments from the date of grant until fully vested and exercisable on August 15, 2027. ( 9 )The shares subject to the option shall vest in 48 equal monthly installments from the date of grant until fully vested and exercisable on February 20, 2027. ( 10 )The shares subject to the option shall vest in 48 equal monthly installments from the date of grant until fully vested and exercisable on May 3, 2025. ( 11 )The shares subject to the option shall vest in 48 equal monthly installments from the date of grant until fully vested and exercisable on March 12, 2024. ( 12 )The shares subject to the option shall vest in 48 equal monthly installments from the date of grant until fully vested and exercisable on July 24, 2021. ( 13 )On July 31, 2026, the reporting person was granted 128,985 performance-vested restricted stock units granted under the Issuer's 2018 equity incentive plan. Each restricted stock unit represents the right to acquire one share of Issuer common stock. The award vests in full, and all restrictions lapse, immediately upon the closing price of the Issuer's common stock equaling or exceeding $72.36 per share for one trading day at any time prior to the third anniversary of the grant date. If this market condition is not satisfied prior to such date, the award will be forfeited in its entirety without consideration on July 31, 2029. The number of shares reported reflects the maximum and only number of shares issuable under the award; there is no target, threshold, or maximum range.

Remarks: The reporting person has authorized and designated the named person to file this Form 3 on the reporting person's behalf for indefinite duration.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.